The Top 5 Biosimilars Articles for the Week of April 20

Here are the top 5 biosimilars articles for the week of April 20, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 20, 2020.

Number 5: A Swedish company that wants to bring a ranibizumab biosimilar to market said it may finish trial enrollment despite the pandemic.

Number 4: 2020 has already seen 4 biosimilar launches in the United States, with potentially several more on the way. Although, the coronavirus disease 2019 (COVID-19) pandemic has introduced a wild card to the mix, according to presenters for the AMCP eLearning Days virtual meeting.

Number 3: Education is often noted as a barrier to uptake, but a prominent pharmacy expert said multiple private and public policies also stand between patients and biosimilars.

Number 2: A percentage of oncology pharmacy practitioners report their guidance on biosimilars is influential with clinicians, but many feel their knowledge of biosimilars is deficient in a number of important areas.

Number 1: In partnership with Samsung Bioepis, Merck has launched the trastuzumab biosimilar, Ontruzant, which marks the fifth trastuzumab biosimilar available on the US market.

To read all of these articles and more, visit